IL21 and systemic lupus erythematosus: To better manipulate CD132 for treating SLE, we conducted a reanalysis on another large-scale transcriptome dataset that included SLE patients with different disease activities.26 The results revealed a significantly elevated expression of IL-21 and its receptor in patients with low disease activity (LDA), with even higher levels in those with high disease activity (HDA) (Fig. 1h).